• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤细胞系中FRA3B区域频繁的纯合缺失仍使FHIT外显子保持完整。

Frequent homozygous deletions in the FRA3B region in tumor cell lines still leave the FHIT exons intact.

作者信息

Wang L, Darling J, Zhang J S, Qian C P, Hartmann L, Conover C, Jenkins R, Smith D I

机构信息

Department of Laboratory Medicine and Pathology, Mayo Clinic/Foundation, Rochester, Maine 55902, USA.

出版信息

Oncogene. 1998 Feb 5;16(5):635-42. doi: 10.1038/sj.onc.1201576.

DOI:10.1038/sj.onc.1201576
PMID:9482109
Abstract

FRA3B at human chromosomal band 3p14.2 is the most active common fragile site in the human genome. The molecular mechanism of fragility at this region remains unknown but does not involve expansion of a trinucleotide or minisatellite repeat as has been observed for several of the cloned rare fragile sites. Deletions and rearrangements at FRA3B have been observed in a number of distinct tumors. The recently identified putative tumor suppressor gene FHIT spans FRA3B, and various groups have reported identifying deletions in this gene in different tumors. Using a high density of PCR amplifiable markers within FRA3B searching for deletions in the FRA3B region, we have analysed 21 tumor cell lines derived from renal cell, pancreatic, and ovarian carcinomas. We found a commonly deleted region in the renal cell and ovarian carcinoma cell lines located in the middle of an HPV16 viral integration site. Despite the presence of deletions in the FRA3B region in most of the cell lines, we did not detect alterations in FHIT exons in any of the cell lines examined. Thus, deletions of 3p14.2 in these carcinoma cell lines may simply reflect instability of the FRA3B region during tumor progression.

摘要

位于人类染色体3p14.2带的FRA3B是人类基因组中最活跃的常见脆性位点。该区域脆性的分子机制尚不清楚,但不像一些已克隆的罕见脆性位点那样涉及三核苷酸或微卫星重复序列的扩增。在许多不同的肿瘤中都观察到了FRA3B处的缺失和重排。最近鉴定出的假定肿瘤抑制基因FHIT跨越FRA3B,不同研究小组报告在不同肿瘤中发现了该基因的缺失。我们利用FRA3B内高密度的可PCR扩增标记物来寻找FRA3B区域的缺失,分析了21种来源于肾细胞癌、胰腺癌和卵巢癌的肿瘤细胞系。我们在肾细胞癌和卵巢癌细胞系中发现了一个常见的缺失区域,该区域位于HPV16病毒整合位点的中间。尽管大多数细胞系的FRA3B区域存在缺失,但在我们检测的任何细胞系中均未检测到FHIT外显子的改变。因此,这些癌细胞系中3p14.2的缺失可能仅仅反映了肿瘤进展过程中FRA3B区域的不稳定性。

相似文献

1
Frequent homozygous deletions in the FRA3B region in tumor cell lines still leave the FHIT exons intact.肿瘤细胞系中FRA3B区域频繁的纯合缺失仍使FHIT外显子保持完整。
Oncogene. 1998 Feb 5;16(5):635-42. doi: 10.1038/sj.onc.1201576.
2
Identification of unstable sequences within the common fragile site at 3p14.2: implications for the mechanism of deletions within fragile histidine triad gene/common fragile site at 3p14.2 in tumors.3p14.2处常见脆性位点内不稳定序列的鉴定:对肿瘤中3p14.2处脆性组氨酸三联体基因/常见脆性位点内缺失机制的启示
Cancer Res. 2002 Jun 15;62(12):3477-84.
3
Frequent breakpoints in the 3p14.2 fragile site, FRA3B, in pancreatic tumors.胰腺肿瘤中3p14.2脆性位点FRA3B的频繁断点。
Cancer Res. 1996 Oct 1;56(19):4347-50.
4
Positions of chromosome 3p14.2 fragile sites (FRA3B) within the FHIT gene.FHIT基因内3号染色体3p14.2脆性位点(FRA3B)的位置。
Cancer Res. 1997 Mar 15;57(6):1166-70.
5
FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations.FHIT和FRA3B 3p14.2等位基因缺失在肺癌和癌前支气管病变中很常见,并且与癌症相关的FHIT cDNA剪接异常有关。
Cancer Res. 1997 Jun 1;57(11):2256-67.
6
Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands.散发性乳腺癌、癌前病变及家族性乳腺癌先证者中FHIT基因与FRA3B区域的分析
Cancer Res. 1997 Sep 1;57(17):3664-8.
7
FHIT gene and the FRA3B region are not involved in the genetics of renal cell carcinomas.脆性组氨酸三联体(FHIT)基因和FRA3B区域不参与肾细胞癌的遗传学过程。
Genes Chromosomes Cancer. 1997 Sep;20(1):9-15.
8
Frequent deletions of FHIT and FRA3B in Barrett's metaplasia and esophageal adenocarcinomas.在巴雷特化生和食管腺癌中,FHIT和FRA3B频繁缺失。
Oncogene. 1997 Oct 2;15(14):1653-9. doi: 10.1038/sj.onc.1201330.
9
Frequent breakpoints in the region surrounding FRA3B in sporadic renal cell carcinomas.散发性肾细胞癌中FRA3B周围区域的频繁断点。
Oncogene. 1997 Mar 20;14(11):1269-77. doi: 10.1038/sj.onc.1201100.
10
Analysis of the fragile histidine triad gene in primary gastric carcinomas and gastric carcinoma cell lines.原发性胃癌及胃癌细胞系中脆性组氨酸三联体基因的分析
Genes Chromosomes Cancer. 1997 Sep;20(1):98-102.

引用本文的文献

1
Break-seq reveals hydroxyurea-induced chromosome fragility as a result of unscheduled conflict between DNA replication and transcription.Break-seq揭示了羟基脲诱导的染色体脆性是DNA复制和转录之间意外冲突的结果。
Genome Res. 2015 Mar;25(3):402-12. doi: 10.1101/gr.180497.114. Epub 2015 Jan 21.
2
Very large common fragile site genes and their potential role in cancer development.非常大的常见脆性位点基因及其在癌症发展中的潜在作用。
Cell Mol Life Sci. 2014 Dec;71(23):4601-15. doi: 10.1007/s00018-014-1753-6. Epub 2014 Oct 10.
3
Interplay between genetic and epigenetic factors governs common fragile site instability in cancer.
遗传因素和表观遗传因素之间的相互作用决定了癌症中常见脆性位点的不稳定性。
Cell Mol Life Sci. 2014 Dec;71(23):4495-506. doi: 10.1007/s00018-014-1719-8. Epub 2014 Oct 9.
4
FAM190A rearrangements provide a multitude of individualized tumor signatures and neo-antigens in cancer.FAM190A重排在癌症中提供了大量个体化的肿瘤特征和新抗原。
Oncotarget. 2011 Jan-Feb;2(1-2):69-75. doi: 10.18632/oncotarget.220.
5
Low levels of WWOX protein immunoexpression correlate with tumour grade and a less favourable outcome in patients with urinary bladder tumours.WWOX蛋白免疫表达水平低与膀胱肿瘤患者的肿瘤分级及较差的预后相关。
Histopathology. 2008 Jun;52(7):831-9. doi: 10.1111/j.1365-2559.2008.03033.x. Epub 2008 Apr 29.
6
Cancer-specific chromosome alterations in the constitutive fragile region FRA3B.组成型脆性区域FRA3B中的癌症特异性染色体改变。
Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7456-61. doi: 10.1073/pnas.96.13.7456.
7
Aberrant FHIT mRNA transcripts are present in malignant and normal haematopoiesis, but absence of FHIT protein is restricted to leukaemia.异常的FHIT信使核糖核酸转录本存在于恶性和正常造血过程中,但FHIT蛋白的缺失仅限于白血病。
Oncogene. 1999 Jan 7;18(1):79-85. doi: 10.1038/sj.onc.1202256.